Like other business around the world, Starpharma continues to closely monitor the COVID-19 pandemic and its impact.

The health and safety of our people, trial patients and VivaGel® customers is paramount. Starpharma has implemented a broad program of measures to protect the health and safety of our staff and clinical trial patients, and to ensure product supply to customers.

Starpharma has a COVID-19 Safe Plan in place. Starpharma’s laboratory and internal operations have continued to operate under this COVID-19 safe plan, with minimal disruption. The COVID-19 safe plan includes mitigation actions in specific areas including stringent hygiene, cleaning, physical distancing, record keeping and response preparation in the event of a suspected or confirmed COVID‑19 case.

Starpharma’s management team continues to monitor the situation and update its policies based on current medical advice and Government directives, as required.